Evidence map›Paper›PMID 32369455›Full record

ArticleJCI insight2020

Inflammescent CX3CR1+CD57+CD8+ T cells are generated and expanded by IL-15.

Stephen R Morris, Bonnie Chen, Joseph C Mudd, Soumya Panigrahi, Carey L Shive, Scott F Sieg, Cheryl M Cameron, David A Zidar, Nicholas T Funderburg, Souheil-Antoine Younes and 4 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. The CX3CL1-CX3CR1 axis in HIV-associated inflammation and cardiometabolic disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  14. Review
  15. Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. T-Cell Senescence in Human Metabolic Diseases.Diabetes & metabolism journal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Stephen R MorrisCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Bonnie ChenCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Joseph C MuddBarrier Immunity Section, Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Soumya PanigrahiCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Carey L ShiveLouis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
Scott F SiegCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Cheryl M CameronCenter for AIDS Research, Department of Nutrition, Case Western Reserve University, Cleveland, Ohio, USA.
David A ZidarLouis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
Nicholas T FunderburgDivision of Medical Laboratory Science, School of Health and Rehabilitation Sciences, Ohio State University, Columbus, Ohio, USA.
Souheil-Antoine YounesCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Benigno RodriguezCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Sara GianellaCenter for AIDS Research, Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Michael M LedermanCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Michael L FreemanCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
University Hospitals of Cleveland · USLouis Stokes Cleveland VA Medical Center · USCase Western Reserve University · USNational Institute of Allergy and Infectious Diseases · USThe Ohio State University · USUniversity of California System · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Case AIDS Clinical Trials UnitU01AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL · 2007 to 2011
$14.7M
Specimen Acquisition and Distribution CoreP01AI076174 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LANDAY, ALAN L · 2008 to 2012
$10.9M
Revealing Reservoirs during Rebound (R3)P01AI131385 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEGRUTTOLA, VICTOR GERARD · 2017 to 2021
$8.7M
Cellular mediators of vascular inflammation in treated HIV-infectionR01HL134544 · NHLBI · OHIO STATE UNIVERSITY · PI FUNDERBURG, NICHOLAS T. · 2016 to 2019
$3.2M
Effect of Declining Sex Hormones on HIV persistence in HIV Infected Women on ARTR21HD094646 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2017 to 2018
$441k
Role of IL-6 and IL-1b in immune dysfunction during aging, HIV, and HCV infectionIK2CX001471 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI SHIVE, CAREY LYNN · 2017 to 2021
–
CSRD VA IK2 CX001471NCATS NIH HHS UL1 TR001442NHLBI NIH HHS R01 HL134544NIAID NIH HHS P01 AI076174NIAID NIH HHS P01 AI131385NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS R24 AI106039NIAID NIH HHS U01 AI069501NIAID NIH HHS UM1 AI069501NICHD NIH HHS R21 HD094646
6 · The paper itself

Abstract

HIV infection is associated with an increase in the proportion of activated CD8+ memory T cells (Tmem) that express CX3CR1, but how these cells are generated and maintained in vivo is unclear. We demonstrate that increased CX3CR1 expression on CD8+ Tmem in people living with HIV (PLWH) is dependent on coinfection with human CMV, and CX3CR1+CD8+ Tmem are enriched for a putatively immunosenescent CD57+CD28- phenotype. The cytokine IL-15 promotes the phenotype, survival, and proliferation of CX3CR1+CD57+CD8+ Tmem in vitro, whereas T cell receptor stimulation leads to their death. IL-15-driven survival is dependent on STAT5 and Bcl-2 activity, and IL-15-induced proliferation requires STAT5 and mTORC1. Thus, we identify mechanistic pathways that could explain how "inflammescent" CX3CR1+CD57+ CD8+ Tmem dominate the overall memory T cell pool in CMV-seropositive PLWH and that support reevaluation of immune senescence as a nonproliferative dead end.

Indexed as

Immunologic MemoryCD57 AntigensCD8-Positive T-LymphocytesCell ProliferationCell SurvivalCX3C Chemokine Receptor 1HIV-1HIV InfectionsHumansInterleukin-15CD57 AntigensCX3C Chemokine Receptor 1CX3CR1 protein, humanIL15 protein, humanInterleukin-15AIDS/HIVCellular immune responseImmunologyT cells

Identifiers

PMID32369455
PMCPMC7346586
OpenAlexW3023278405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.